Tubulis’ next-generation antibody-drug conjugate (ADC) has been tied to an overall response rate (ORR) of 59% as the German ...
PEGylation and glycosylation as bioconjugation tools for drug development: New webinar tackles complex chemistry for targeted ...
Europe’s leading cancer conference may be swimming in antibody-drug conjugate data, but AstraZeneca remains convinced that ...
MedPage Today on MSN
Trastuzumab Deruxtecan Scores Two Wins in HER2-Positive Early Breast Cancer
BERLIN -- The antibody-drug conjugate (ADC) trastuzumab deruxtecan (T-DXd, Enhertu) delivered impressive results in different ...
AbbVie has announced new clinical data from its antibody-drug conjugate (ADC) platform, reinforcing its commitment to ...
A novel trivalent vaccine targeting typhoid fever and invasive non-typhoidal Salmonella (iNTS) infections has demonstrated ...
More than 40,000 Americans die from the respiratory illness each year, and over 1.4 million adults seek care in a hospital.
Medical writing assistance was provided by Yolande Chalmers, EMJ, London, UK. The views and opinions expressed in this ...
R-DXd showed a 50.5% objective response rate in platinum-resistant ovarian cancer, with a 5.6 mg/kg dose deemed optimal for further study. The safety profile was manageable, with 93.5% experiencing ...
Sejeong Son of FirstLaw PC draws on three cases to explain how South Korean courts are reinterpreting the territoriality ...
Discover the emerging field of AI-based peptide discovery and design – could this signal the beginning of a golden age for ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback